Glenmark Pharmaceuticals Limited

rs,

vember 10, 2023 To, Dy. General Manager Department of Corporate Services, BSE Ltd., P. J. Towers, Dalal Street, Fort, Mumbai – 400 001 To, The Manager – Listing, National Stock Exchange of Indi

100%

icals Ltd. All Rights Reserved Strategic Restructuring For Sharper Focus On The Three Businesses (100% subsidiary) U.S. headquartered, innovation biotech company focused on development of novel biolo

82.84%

ocused on development of novel biological molecules as potential treatment options for oncology (82.84% subsidiary) Focused on manufacturing and marketing of API products across all the major global ma

3 million

year 2025** Zero waste to landfill at all our plant locations by the year 2027 Aspire to impact 3 million lives by 2025 Deepen global presence and deliver quality affordable in new markets Continue focu

Rs. 35,879

Q2 & 6M FY24 Snapshot – Consolidated (GPL + GLS) Q2 FY24 6M FY24  Revenues from Operations at Rs. 35,879 Mn with a growth of  Revenues from Operations at Rs. 69,895 Mn with a growth of 6.3% YoY 13.6%

Rs. 69,895

FY24  Revenues from Operations at Rs. 35,879 Mn with a growth of  Revenues from Operations at Rs. 69,895 Mn with a growth of 6.3% YoY 13.6% YoY  Adjusted EBITDA* of Rs. 6,732 Mn with margin of 18.8%

6.3%

at Rs. 35,879 Mn with a growth of  Revenues from Operations at Rs. 69,895 Mn with a growth of 6.3% YoY 13.6% YoY  Adjusted EBITDA* of Rs. 6,732 Mn with margin of 18.8%  Adjusted EBITDA* of Rs.

13.6%

,879 Mn with a growth of  Revenues from Operations at Rs. 69,895 Mn with a growth of 6.3% YoY 13.6% YoY  Adjusted EBITDA* of Rs. 6,732 Mn with margin of 18.8%  Adjusted EBITDA* of Rs. 13,045 Mn w

Rs. 6,732

nues from Operations at Rs. 69,895 Mn with a growth of 6.3% YoY 13.6% YoY  Adjusted EBITDA* of Rs. 6,732 Mn with margin of 18.8%  Adjusted EBITDA* of Rs. 13,045 Mn with margin of 18.7%  Consolidated Re

18.8%

69,895 Mn with a growth of 6.3% YoY 13.6% YoY  Adjusted EBITDA* of Rs. 6,732 Mn with margin of 18.8%  Adjusted EBITDA* of Rs. 13,045 Mn with margin of 18.7%  Consolidated Revenue of Rs. 35,879 Mn;

Rs. 13,045

6.3% YoY 13.6% YoY  Adjusted EBITDA* of Rs. 6,732 Mn with margin of 18.8%  Adjusted EBITDA* of Rs. 13,045 Mn with margin of 18.7%  Consolidated Revenue of Rs. 35,879 Mn; growth of 6.3% YoY  Consolidated

18.7%

ed EBITDA* of Rs. 6,732 Mn with margin of 18.8%  Adjusted EBITDA* of Rs. 13,045 Mn with margin of 18.7%  Consolidated Revenue of Rs. 35,879 Mn; growth of 6.3% YoY  Consolidated Revenue of Rs. 69,895